Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Oregon Pulmonary Associates, PC
mi
from
Portland, OR
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Oregon Pulmonary Associates, PC
mi
from
Portland, OR
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Penn Presbyterian Medical Center
mi
from
Philadelphia, PA
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Penn Presbyterian Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Medical Center
mi
from
Nashville, TN
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Texas-Houston Health Center Department of Pulmonary & Critical Care
mi
from
Houston, TX
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Texas-Houston Health Center Department of Pulmonary & Critical Care
mi
from
Houston, TX
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital-Department of Medicine
mi
from
Madison, WI
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital-Department of Medicine
mi
from
Madison, WI
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
St. Luke's Medical Center
mi
from
Milwaukee, WI
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
mi
from
Buenos Aires,
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
mi
from
Buenos Aires,
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Georgia Regents Univ/ Augusta Univ
mi
from
Augusta, GA
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Georgia Regents Univ/ Augusta Univ
mi
from
Augusta, GA
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Piedmont Healthcare Pulm & Crit Care Research
mi
from
Austell, GA
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Piedmont Healthcare Pulm & Crit Care Research
mi
from
Austell, GA
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital
mi
from
Troy, MI
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital
mi
from
Troy, MI
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine, Houston Methodist Hospital
mi
from
Houston, TX
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine, Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Froedtert Hospital, Pulm & Critical Care
mi
from
Milwaukee, WI
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Froedtert Hospital, Pulm & Critical Care
mi
from
Milwaukee, WI
Click here to add this to my saved trials
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Click here to add this to my saved trials
Systolic Blood Pressure Intervention Trial
Systolic Blood Pressure Intervention Trial
Status: Enrolling
Updated:  12/31/1969
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Systolic Blood Pressure Intervention Trial
Systolic Blood Pressure Intervention Trial
Status: Enrolling
Updated: 12/31/1969
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miramar, FL
A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miramar, FL
Click here to add this to my saved trials
A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension
A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension
Status: Enrolling
Updated:  12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension
A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension
Status: Enrolling
Updated: 12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Status: Enrolling
Updated:  12/31/1969
Various
mi
from
Los Angeles, CA
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Status: Enrolling
Updated: 12/31/1969
Various
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study
PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES IN INDUCED PLURIPOTENT STEM (IPS) CELLS STUDY (PEAR-IPSC) (PEAR-iPSC)
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study
PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES IN INDUCED PLURIPOTENT STEM (IPS) CELLS STUDY (PEAR-IPSC) (PEAR-iPSC)
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0
The Minority Health Genomics and Translational Research BIo-Repository Database (MH-GRID)-2.0
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0
The Minority Health Genomics and Translational Research BIo-Repository Database (MH-GRID)-2.0
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Sall Medical Research Center
mi
from
Artesia, CA
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Sall Medical Research Center
mi
from
Artesia, CA
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Vold Vision, PLLC
mi
from
Fayetteville, AR
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Vold Vision, PLLC
mi
from
Fayetteville, AR
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Eye Research Foundation
mi
from
Newport Beach, CA
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Eye Research Foundation
mi
from
Newport Beach, CA
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Clayton Eye Center
mi
from
Morrow, GA
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Mundorf Eye Center
mi
from
Charlotte, NC
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Mundorf Eye Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Cornerstone Health Care; Cornerstone Eye Care
mi
from
High Point, NC
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Cornerstone Health Care; Cornerstone Eye Care
mi
from
High Point, NC
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
University Eye Specialists
mi
from
Maryville, TN
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
University Eye Specialists
mi
from
Maryville, TN
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
Total Eye Care, PA
mi
from
Memphis, TN
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
Total Eye Care, PA
mi
from
Memphis, TN
Click here to add this to my saved trials
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated:  12/31/1969
R and R Eye Research, LLC
mi
from
San Antonio, TX
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Status: Enrolling
Updated: 12/31/1969
R and R Eye Research, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
A ED-based Intervention to Improve Antihypertensive Adherence
A Randomized, ED-based Intervention to Improve Antihypertensive Adherence
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
A ED-based Intervention to Improve Antihypertensive Adherence
A Randomized, ED-based Intervention to Improve Antihypertensive Adherence
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic -Clinical Studies Unit
mi
from
Phoenix, AZ
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic -Clinical Studies Unit
mi
from
Phoenix, AZ
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
UCSD
mi
from
La Jolla, CA
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
UCSD
mi
from
La Jolla, CA
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Univ. of Florida College Medicine
mi
from
Jacksonville, FL
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Univ. of Florida College Medicine
mi
from
Jacksonville, FL
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida - Pulmonary Dept.
mi
from
Jacksonville, FL
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida - Pulmonary Dept.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Emory Healthcare
mi
from
Atlanta, GA
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Emory Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Piedmont Healthcare
mi
from
Austell, GA
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Piedmont Healthcare
mi
from
Austell, GA
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Health Science Center
mi
from
Albuquerque, NM
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Health Science Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials